UNSPSC 51333505: Penfluridol

This classification denotes a dopamine antagonist with the molecular formula C28H27ClF5NO, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 25TLU22Q8H, chemically known as 4-piperidinol, 4-(4-chloro-alpha,alpha,alpha-trifluoro-m-tolyl)-1-(4,4-bis(p-fluorophenyl)butyl)- but generally known as penfluridol, which bears US NIH Compound Identifier 33630. European Medicines Agency schedules Penfluridol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09664MIG.

UNSPSC 51333505 Penfluridol is a Commodity code that maps to pharmaceutical supply procurement, though recent state and local solicitations under this designation show limited direct activity for the specific active ingredient. The three recent opportunities tagged to this code reflect broader pharmaceutical and drug-management procurement across state health agencies and county public health departments — Seminole County, Florida seeking naloxone and drug deactivation systems; the Texas Health and Human Services Commission exploring direct-to-manufacturer prescription programs; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) establishing statewide contracts for generic multi-source pharmaceuticals and over-the-counter products. The issuing bodies span county health systems, state health agencies, and cooperative purchasing organizations serving multiple jurisdictions, indicating that pharmaceutical procurement under this code involves both individual county initiatives and coordinated multi-state contracting vehicles.

Geographic activity centers on Florida, Texas, and Minnesota based on recent postings. The Seminole County IFB (Solicitation IFB60459723LAS, due July 26, 2023) sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, representing a direct public health procurement. The Texas HHS RFI (HHS0017013, posted April 3, 2026) focused on vendor capacity for direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager channels. The MMCAP RFP (S1070000015802, due March 26, 2026) established multi-contract awards for generic pharmaceuticals and OTC products across authorized wholesalers including AmerisourceBergen, Cardinal Health, and Morris & Dickson, effective July 1, 2026, with vendors required to maintain cGMP and Drug Supply Chain Security Act compliance and pay a 3 percent administrative fee on all purchases. The code shows recent activity but limited direct solicitation volume for penfluridol specifically, with broader pharmaceutical procurement dominating state and local agency requests.